A Comparison of Transnasal Versus Ultrasound-guided Suprazygomatic Approaches for Sphenopalatine Ganglion Blocks in Persistent Idiopathic Facial Pain
Sponsor study identifier
observational
40
1 country
1
Study Start
October 1, 2022
Actual (reported)Primary Completion
April 1, 2023
Actual (reported)Study Completion
April 2, 2023
Actual (reported)The International Headache Society defines persistent idiopathic facial pain (PIFP) as persistent facial pain that does not have the characteristics of cranial neuralgia, is blunt, persistent, persistent, bothersome and not attributable to another disorder. The management of persistent idiopathic facial pain (PIFP) is complex. The sphenopalatine ganglion (SPG) has been the target of interventional treatment of many facial pain syndromes. The sphenopalatine ganglion can be accessed by transnasal access and ultrasound or scopy guidance. In this study, datas compared the efficacy of transnasal approach and ultrasound-guided suprazigomatic approach in sphenopalatine ganglion block in patients with persistent idiopathic facial pain.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
April 2, 2023
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 1, 2022
Actual (reported)April 1, 2023
Actual (reported)April 2, 2023
Actual (reported)July 4, 2024
Actual (reported)July 11, 2024
Actual (reported)Numerical Rating Scale (NRS)
NRS is a pain screening Scale, in time using a 0-10 Scale, with zero meaning ''no pain'' and 10 meaning ''the worst pain imaginable''.
Change from baseline to 1st hour, 1st week and 4th weeks after treatment
HIT-6 (Headache impact test)
Change from baseline to 1st hour, 1st week and 4th weeks after treatment
transnasal administration of lidocaine to the sphenopalatine ganglion
ultrasound-guided suprazygomatic approach
The transnasal approach to the sphenopalatine ganglion block allows for non-invasive access to the sphenopalatine ganglion, which is located deep in the nasopharynx in a recess posterior to the middle turbinate. A long cotton swab is inserted posterior to the nasopharynx until it is properly seated, and 2 mL of 2% lidocaine is injected through the outer end of the swab and left for 30 minutes. Patients are monitored for any potential complications or adverse effects throughout the procedure and for a period of time afterwards.
Male and female patients who underwent transnasal or ultrasound-guided suprazygomatic sphenopalatin ganglion block for persistant idiopathic facial pain
Ankara Etlik City Hospital
Ankara, Yenimahalle, 06100, Turkey (Türkiye)
Ömer Taylan Akkaya, MD
Diskapi Teaching and Research Hospital
Ezgi Can, MD
Diskapi Teaching and Research Hospital
40 participants (actual enrollment reported by the registry).
First Submitted
July 4, 2024
First Posted
July 11, 2024
Study Start
October 1, 2022
Actual (reported)SPG Blocks for Headaches
Comparison of Occipital Nerve and Sphenopalatine Ganglion Blockade
The ultrasound transducer is placed in the infrazygomatic area, above the maxilla, at approximately a 45 cephalad angle. With this transducer position, the ptrigopalatine fossa, bounded anteriorly by the maxilla and posteriorly by the pterygoid process, is visualized. A 25 gauge spinal needle is inserted 1 to 1.5 cm above the zygomatic arch and posterior to the posterior orbital rim and advanced through an out-of-plane approach to reach the pterigolapalatine fossa. After the aspiration test, 3 mL of 2% lidocaine is injected and the spread of the drug is monitored by ultrasound. Patients are monitored for possible side effects and complications.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
April 1, 2023
Actual (reported)Study Completion
April 2, 2023
Actual (reported)Last Updated
August 5, 2024
Record last verified: 2024-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: